News

13 May 2016

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

Proteon Therapeutics Inc., a collaborator of Biopta, today announced publication of additional nonclinical data on Vonapanitase, an investigational drug under development to improve Arteriovenous Fistula (AVF) maturation and patency in chronic kidney disease patients.
Read More >>

21 Apr 2016

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

Proteon Therapeutics Inc. a collaborator of Biopta, today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD).
Read More >>

25 Nov 2015

Biopta to be acquired by Japanese stem cell company ReproCELL

Biopta is to be acquired by the stem cell and regenerative medicine company ReproCELL. The deal will help Biopta to expands its range of drug discovery services based on human fresh tissues.
Read More >>

18 Nov 2015

Biopta co-authors research in the European Respiratory Journal

The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.
Read More >>

1 2 3 4 >>

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

21/04/2016

Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease

Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD). The ex vivo study demonstrated that a single treatment of vonapanitase following angioplasty of excised atherosclerotic human tibial arteries altered artery compliance. Increased compliance is known to correlate with arterial dilation.

The study, titled Recombinant Human Elastase Alters the Compliance of Atherosclerotic Tibial Arteries After Ex Vivo Angioplasty, was published in the Journal of Cardiovascular Pharmacology. Proteons Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors. Proteon's press release can be read here

Live chat by BoldChat